|
Antisense Therapeutics Extends its Drug Discovery and Development Collaboration with Isis Pharmaceuticals |
|
|
|
06 Feb 2007 |
Antisense Therapeutics Ltd. (ANP) is pleased to announce that it and Isis Pharmaceuticals have agreed to extend their drug discovery and development collaboration for a further two years.
TOORAK, Australia | Feb 05, 2007 | Antisense Therapeutics Ltd. (ANP) is pleased to announce that it and Isis Pharmaceuticals have agreed to extend their drug discovery and development collaboration for a further two years.
The original collaboration agreement which commenced in December 2001 allows ANP to select, test and assess new antisense compounds for a variety of diseases and potential commercial markets. The intent of this agreement and its extension is to add new products to ANP’s current drug development pipeline which includes ATL1102 for multiple sclerosis and ATL1103 for growth and sight disorders, the latter of which is a direct product of this active collaboration.
The collaboration agreement facilitates ANP holding world-wide exclusive licenses to any of those drugs which it ultimately decides to develop and commercialise.
“We are delighted to be able to continue our discovery and development collaboration with Isis who are world leaders in antisense technology and its application,” said Mark Diamond, CEO of Antisense Therapeutics. “We know that there is growing international interest in the clinical application of Isis’ antisense technology and thus the extension of these rights adds considerable value to our company. Exploiting our development collaboration with Isis remains the quickest and most cost effective way for the Company to expand its pipeline with high quality drug candidates.”
C. Frank Bennett, Ph.D., Isis' Senior Vice President of Research, commented, “ANP is an example of Isis’ partnering strategy in which we partner Isis assets with high-quality organizations, such as ANP, to broaden the number of antisense drugs in development. Isis is pleased to extend its drug discovery and development collaboration with ANP. The past five years have been very productive with the advancement of ATL1102 into Phase 2 clinical trials and the identification of two additional clinical development candidates out of the collaboration. We have a great relationship with ANP and look forward to advancing additional drugs into the clinic.”
About Antisense Therapeutics Limited
Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. Isis Pharmaceuticals is a major shareholder of ANP (more information about Isis is available at www.isispharm.com ) .
Contact Information: Website: www.antisense.com.au
Managing Director – Mark Diamond +61 3 9827 8999
Company Secretary – Phillip Hains +61 3 9824 5254
Media – Market Connect (Simon Watkin) +61 3 9686 9931
SOURCE: Antisense Therapeutics Ltd. |
